2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Related Products

PDF 0.57 MB

Polo-like Kinases (PLKs) are a group of highly conserved serine/threonine protein kinases that play a key role in processes such as cell division and checkpoint regulation of mitosis. In mammals, five PLKs (PLK 1-5) encompass diverse roles in centrosome dynamics, spindle formation, intra S-phase and G2/M checkpoints, and DNA damage response.

PLKs are characterized by their Polo-box domain, which mediates protein interactions. They are additionally controlled by phosphorylation, proteolysis, and transcription, depending on the biological context. PLKs are now recognized to link cell division to developmental processes and to function in differentiated cells.

Polo-like Kinase (PLK) Isoform Specific Products:

Polo-like Kinase (PLK) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-112395
    BTO-1
    		Inhibitor
    BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications.
    BTO-1
  • HY-181000
    PROTAC PLK1 Degrader-3
    		Degrader
    PROTAC PLK1 Degrader-3 (Compound DD-1) is a PLK1 PROTAC degrader based on the N-deglycosylation pathway, with a Kd value of 2.2 μM. The cell penetration ability of PROTAC PLK1 Degrader-3 is limited and a higher concentration is required to achieve significant degradation effects. PROTAC PLK1 Degrader-3 can be used for research on non-small cell lung cancer.
    PROTAC PLK1 Degrader-3
  • HY-W338346
    Salicylate choline
    		Inhibitor
    Salicylate choline is an orally active derivative of Aspirin (acetylsalicylic acid) (HY-14654). Salicylate choline significantly reduces IL-1β, IL-6, TNF-α and IL-10 levels in cells. Salicylate choline enhances the anti-tumor activity of the CRM1 inhibitor Selinexor (KPT-330) (HY-17536) through inducing S-phase cell cycle arrest and impairing DNA damage repair. Salicylate choline combined with Selinexor demonstrates excellent anti-tumor efficacy in mice xenograft model harboring JeKo-1 cells. Salicylate choline can be used for the study of rheumatic diseases, inflammation and cancer.
    Salicylate choline
  • HY-10197R
    Wortmannin (Standard)
    		Inhibitor
    Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively.
    Wortmannin (Standard)
  • HY-RS10721
    Plk4 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Plk4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk4 Mouse Pre-designed siRNA Set A
  • HY-50698G
    BI 2536 (GMP)
    		Inhibitor
    BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription.
    BI 2536 (GMP)
  • HY-RS10715
    Plk2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Plk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk2 Mouse Pre-designed siRNA Set A
  • HY-155377
    PLK1/p38γ-IN-1
    		Inhibitor
    PLK1/p38γ-IN-1(compound 14) is a multitarget inhibitors ofPLK1andp38γ. PLK1/p38γ-IN-1inhibits the growth of human hepatocellular carcinoma and hepatoblastoma cells in vitro.
    PLK1/p38γ-IN-1
  • HY-W162436
    MCC1019
    		Inhibitor
    MCC1019 is a selective PLK1 PBD inhibitor with an IC50 of 16.4 μmol/L. MCC1019 inactivates the AKT signaling pathway in cancer cells, and induces Apoptosis, Necroptosis and Autophagy. MCC1019 exhibits anticancer activity against lung cancer and prostate cancer.
    MCC1019
  • HY-181616
    p53-Y220C/PLK1 modulator-1
    		Modulator
    p53-Y220C/PLK1 modulator-1 (compound15) is a dual modulator targeting p53-Y220C and PLK1. p53-Y220C/PLK1 modulator-1 can be used in the cancer.
    p53-Y220C/PLK1 modulator-1
  • HY-RS10720
    PLK4 Human Pre-designed siRNA Set A
    		Inhibitor

    PLK4 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PLK4 Human Pre-designed siRNA Set A
  • HY-121634
    DAP-81
    		Inhibitor
    DAP-81 is an inhibitory agent targeting Polo-like kinases (Plks), a class of evolutionarily conserved serine/threonine kinases. DAP-81 dose-dependently increases the number of monopolar spindles in treated cells. High-resolution live-cell microscopy revealed that Plk activity is required for the assembly and maintenance of bipolar mitotic spindles. Plk inhibition destabilizes centromeric microtubules while stabilizing other spindle microtubules, leading to the formation of monopolar spindles. Further testing of compounds based on "privileged scaffolds" such as the DAP scaffold may lead to the discovery of new cell division probes and anti-microtubule agents.
    DAP-81
  • HY-123702
    CAP-53194
    CAP-53194 is a selective Plk1 inhibitor with potential anticancer activity. CAP-53194 was identified by a high-throughput virtual screening approach using molecular docking, showing 100-fold selectivity for Plk1 over Plk2-4 and other cell cycle kinases. CAP-53194 is able to effectively exploit subtle differences between the binding sites of Plk1 and other Ser/Thr kinases, thereby enhancing their inhibitory effects. CAP-53194 meets the Lipinski compound analog criteria and passes other ADMET filters, indicating good compound compatibility. CAP-53194 belongs to a new class of potential Plk1 inhibitors suitable for subsequent compound development and testing.
    CAP-53194
  • HY-162895
    NL13
    		Inhibitor
    NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 μM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 μM and 2.53 μM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth.
    NL13
  • HY-149100
    PLK1-IN-6
    		Inhibitor
    PLK1-IN-6 is a potent and selective PLK1 inhibitor, with an IC50 of 0.45 nM. PLK1-IN-6 shows significant anti-proliferative activities against cancer cells.
    PLK1-IN-6
  • HY-175000
    L14-8
    		Degrader
    L14-8 is a potent ferroptosis inducer. L14-8 promotes PLK1 degradation via ubiquitination, increasing TP53 phosphorylation to enhance SAT1 transcription, thereby triggering ferroptosis and cancer cell death. L14-8 can be used for the study of advanced prostate cancer.
    L14-8
  • HY-RS10712
    Plk1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Plk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk1 Mouse Pre-designed siRNA Set A
  • HY-143471
    WNY0824
    		Inhibitor
    WNY0824 (PLK1/BRD4-IN-1) is an orally active dual inhibitor of PLK1 and BET protein families, with IC50 values ​​of 22, 402.5, 150.7, 103.9, and 311.9 nmol/L for PLK1, BRD2, BRD3, BRD4, and BRDT, respectively. WNY0824 induces cell cycle arrest and apoptosis by inhibiting AR- and MYC-mediated transcriptional processes. In addition, WNY0824 also inhibits tumor growth in Enzalutamide (HY-70002) resistant CRPC xenograft tumor models.
    WNY0824
  • HY-176734
    CZL-S092
    		Inhibitor
    CZL-S092 is a PLK4 inhibitor with an IC50 value of 0.9 nM and excellent selectivity over other PLK4 family members (PLK1, PLK2, and PLK3). CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC50 = 1.143 μM). CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer.
    CZL-S092
  • HY-180990
    POI ligand-3
    		Inhibitor
    POI ligand-3 (Compound 4j) is a type of peptide-based PLK1 PBD inhibitor. POI ligand-3 can act as a target protein ligand and be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989).
    POI ligand-3
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Polo-like Kinase (PLK) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.